Overview

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequenci

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-20

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, single-center study. This translational study aims to explore tumor microenvironment remodelling after induction therapy lorlatinib and identify mechanisms of disease persistence and potential primary resistance mechanisms of lorlatinib as induction therapy treatment in surgically resectable ALK-rearranged NSCLC by single-cell RNA sequencing (scRNA-seq) and Spatial transcriptomics.

Phase:

PHASE4

Details

Lead Sponsor:

The First Affiliated Hospital of Guangzhou Medical University

Treatments:

Drug Therapy
lorlatinib